| Literature DB >> 30801336 |
Devon Charlton, Siamak Moghadam-Kia, Kristin Smith, Rohit Aggarwal, Joseph C English, Chester V Oddis.
Abstract
ABSTRACT: Dermatomyositis (DM) is a subset of idiopathic inflammatory myopathy with characteristic cutaneous manifestations and muscle weakness. Conventional treatments for DM include glucocorticoids and other immunosuppressive or immunomodulatory agents including hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, and intravenous immunoglobulin. Refractory patients require more aggressive or novel therapies. Apremilast has not been studied for the management of refractory cutaneous DM. We report a case of a patient with refractory DM with severe scalp pruritus treated with apremilast who demonstrated significant improvement in her skin disease and complete resolution of scalp pruritus.Entities:
Mesh:
Substances:
Year: 2021 PMID: 30801336 DOI: 10.1097/RHU.0000000000000999
Source DB: PubMed Journal: J Clin Rheumatol ISSN: 1076-1608 Impact factor: 3.517